Insights
Would Waiving COVID-19 Vaccines Patents Save Lives?
18 May 2021
This blog discusses the rationale behind a COVID-19 patent waiver decision and contributes to the current debate by producing a balanced view on the benefits and…
Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?
29 April 2021
A team at the University of York recently published a study in which they sought to generate more reliable evidence to inform the estimation of marginal…
Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic
21 April 2021
In this blog, we reflect on some of the key learnings from the recent pull and push strategies to develop COVID-19 vaccines in the UK, the…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
A new paper explores the equivalence of Multi-Criteria Decision Analysis and Augmented Cost-Effectiveness Analysis in adding elements of value to QALY-based cost-effectiveness decision making. It finds…
Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System
31 March 2021
In the contentious debate around US drug prices, less well understood is: if the price of a drug is a fair, value-based, price, how we assess…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of…
Efficiency Measurement in Primary Care: Time to Overcome the Challenges and Achieve Some Gains
10 March 2021
Why is the measurement of efficiency in health care so important, but equally challenging? And why is it especially so in primary care? This blog provides…
International Women’s Day: Why We #Choosetochallenge
8 March 2021
On International Women’s Day, OHE recognises the ongoing need to call out gender inequality, celebrates the achievements made in the health economics community, and reflects on why gender diversity is a ‘no-brainer’ for us as an organisation.
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
A new paper, published last week in Applied Economics, by Dimitrios Kourouklis, Senior Economist at OHE, looks at the question of whether government funding increases public…